Pharming’s Portfolio Grows As Ultra-Rare Disease Drug Joenja Is Approved
Priced At $547,500 Per Year
Executive Summary
The first ever approval for ultra-rare immunodeficiency disease APDS gives Pharming its second product on the market but patient diagnosis will be a major challenge.
You may also be interested in...
EMA Decision Due For Minoryx’s Leriglitazone & Apellis’ Pegcetacoplan
The European Medicines Agency is this week due to decide whether to back pan-EU marketing authorization for five new medicines, including a combination antibiotic product and a drug for chemotherapy-induced neutropenia.
Novartis Nominates Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.
Corbus And Janux Lead Q1’s Small-Cap Winners
Corbus has presence in both antibody drug conjugates and obesity, and was the stand-out small-cap target for investors with a fivefold increase in its share price in Q1.